z-logo
open-access-imgOpen Access
<p>Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study</p>
Author(s) -
Ning An,
Haoyi Wang,
Ji Li,
Xuechao Zhai,
Jing Wang,
Wang Jia,
Li Kong,
Hui Zhu,
Jinming Yu
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s223216
Subject(s) - medicine , oncology , brain metastasis , radiation therapy , retrospective cohort study , incidence (geometry) , lung cancer , progression free survival , cancer , metastasis , chemotherapy , physics , optics
Non-small cell lung cancer (NSCLC) patients with EGFR mutation are suffering from a high incidence of brain metastasis (BM). It is still controversial whether cranial radiotherapy could be delayed when the EGFR-tyrosine kinase inhibitors (TKIs) used as first-line therapy for EGFR-positive patients with BM. This study aims to investigate the therapeutic effect of TKIs combined with concurrent cranial radiotherapy on BM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here